Background {#Sec1}
==========

Non-small-cell lung cancer (NSCLC) has recently been divided into nonsquamous cell carcinoma and squamous cell carcinoma. Pemetrexed and bevacizumab have been approved for the treatment of nonsquamous cell lung cancer \[[@CR1], [@CR2]\]. In addition, epidermal growth factor receptor (*EGFR*) mutations and anaplastic lymphoma kinase (*ALK*) fusion genes have been identified in lung adenocarcinoma, and are considered as biomarkers for EGFR and ALK inhibitors \[[@CR3]--[@CR7]\]. Treatment for nonsquamous cell lung cancer has therefore advanced, including options for personalized therapy.

Squamous cell lung cancer is a major histological subtype of NSCLC, accounting for 30% of NSCLC. However, in contrast to adenocarcinomas, little progress has been achieved in the development of efficacious molecular targeted therapies for squamous cell lung cancer. Comprehensive genome-wide characterization of squamous cell lung cancer has recently revealed some potential drug targets \[[@CR8]--[@CR10]\]. However, differences in frequencies of some genetic alterations, including *EGFR* and *KRAS* mutations, have been identified between Asian and Western patients \[[@CR11]\], and it is therefore important to assess the frequencies of genetic alterations in squamous cell lung cancer in different ethnic groups, including in Asian patients.

We developed a tumor-genotyping panel to screen lung cancer patients for genetic alterations relevant to novel molecular-targeted therapeutics in ongoing clinical trials \[[@CR12]--[@CR15]\] (Additional file [1](#MOESM1){ref-type="media"}: Table S1). Genotyping analysis was implemented in the Shizuoka Lung Cancer Mutation Study, which is a prospective tumor-genotyping study conducted in patients admitted to Shizuoka Cancer Center with thoracic malignancies. This paper reports the results of this study in relation to genetic alterations in squamous cell lung cancer and adenosquamous carcinoma.

Methods {#Sec2}
=======

Patients and samples {#Sec3}
--------------------

The Shizuoka Lung Cancer Mutation Study was initiated in July 2011 to analyze driver mutations in patients with thoracic malignancies. The study subjects were patients with pathologically-diagnosed thoracic malignancies, who had provided written informed consent. The diagnosis and differentiation of squamous cell carcinoma and adenosquamous carcinoma were confirmed by institutional pathologists, in accordance with the 2004 World Health Organization classification. When samples were difficult to diagnose as squamous cell carcinoma, immunohistochemical analyses were performed (i.e., thyroid transcription factor 1, p63 staining). Surgically-resected tissue specimens were macrodissected by the same pathologists to enrich the tumor content. Tumor biopsy specimens containing ≥10% tumor content, as evaluated by hematoxylin-eosin staining, were used for this study. All specimens from 129 patients with squamous cell lung cancer were thus considered adequate for genotyping. Surgically-resected tissues were snap-frozen on dry ice immediately after resection and stored at -80°C until use. Formalin-fixed, paraffin-embedded (FFPE) specimens, mainly including biopsy samples, were sectioned at a thickness of 10 μm. All the relevant clinicopathological information, including smoking history, was retrieved from the patients' medical records. We defined "light smokers" as those who smoked \<30 packs per year, and "heavy smokers" as those who smoked ≥30 packs per year.

Genetic profiling {#Sec4}
-----------------

We developed a tumor genotyping panel (Table [1](#Tab1){ref-type="table"}) to assess 24 hot-spot sites of genetic alterations in 10 genes (*EGFR*, *KRAS*, *BRAF*, *PIK3CA*, *NRAS*, *MEK1*, *AKT1*, *PTEN, HER2* and *DDR2*), *EGFR*, *MET*, *PIK3CA*, *FGFR1* and *FGFR2* copy number gains, and *EML4-ALK*, *KIF5B-RET*, *CCDC6-RET, CD74-ROS1* and *SLC34A2-ROS1* fusion genes using pyrosequencing plus capillary electrophoresis, quantitative polymerase chain reaction (PCR), and reverse-transcription PCR, respectively. These genetic alterations were selected based on the articles listed in Additional file [1](#MOESM1){ref-type="media"}: Table S1. Detailed methods are described in Additional file [2](#MOESM2){ref-type="media"} \[[@CR16]\]. Fusion genes were accessed only with fresh-frozen tissues.Table 1**Multiple tumor genotyping panel**GenePositionAA mutantNucleotide mutant*EGFR*G719G719C/S2155G \> T/AG719A2156G \> Cexon 19deletionT790T790M2369C \> Texon 20insertionL858L858R2573 T \> GL861L861Q2582 T \> A*KRAS*G12G12C/S/R34G \> T/A/CG12V/A/D35G \> T/C/AG13G13C/S/R37G \> T/A/CG13D/A38G \> A/CQ61Q61K181C \> AQ61R/L182A \> G/TQ61H183A \> T/C*BRAF*G466G466V1397G \> TG469G469A1406G \> CL597L597V1789C \> GV600V600E1799 T \> A*PIK3CA*E542E542K1624G \> AE545E545K/Q1633G \> A/CH1047H1047R3140A \> G*NRAS*Q61Q61K181C \> AQ61L/R182A \> T/G*MEK1 (MAP2K1)*Q56Q56P167A \> CK57K57N171G \> TD67D67N199G \> A*AKT1*E17E17K49G \> A*PTEN*R233R233\*697C \> T*HER2*exon 20insertion*DDR2*S768S768R2304 T \> A

Statistical analysis {#Sec5}
--------------------

All categorical variables were analyzed by *χ*^2^ or Fisher's exact tests, as appropriate. All p values were reported as two-sided, and values \<0.05 were considered statistically significant. This study was approved by the Institutional Review Board of the Shizuoka Cancer Center (22-34-22-1-7).

Results {#Sec6}
=======

Patient characteristics {#Sec7}
-----------------------

A total of 129 patients were diagnosed with squamous cell lung cancer or adenosquamous carcinoma and were included in this study from July 2011 to November 2012. The characteristics of the patients are shown in Table [2](#Tab2){ref-type="table"}. The median age was 70 years (range: 38--92), and most patients were male and smokers. Histologically, adenosquamous carcinoma was observed in six (5%) of the patients. Well-differentiated, moderately-differentiated and poorly-differentiated squamous cell carcinomas were present in 10%, 53% and 27% of the patients, respectively. Stage I, II, III and IV were observed in 26%, 29%, 26% and 19%, respectively. Surgically-resected, snap-frozen samples were obtained from 64 patients (50%), and FFPE samples from 65 patients (50%).Table 2**Patient characteristics (overall, n =129)**N =129(%)Median age (years)70    (range)(38--92)Gender    Male11186    Female1814Smoker    Never32    Light (pack-year \<30)129    Heavy (pack-year ≥30)11489Histology    Squamous12395    Adenosquamous65Differentiation    Well1310    Moderately6953    Poorly3527    Unknown65Stage    I3326    II3829    III3426    IV2419

Genetic alteration profiles {#Sec8}
---------------------------

We detected genetic alterations in 40% of all cases. Figure [1](#Fig1){ref-type="fig"} shows the frequencies of genetic alterations in patients with squamous cell lung cancer. The genetic alterations included: *EGFR* mutation in eight (6%); *KRAS* mutation in five (4%); *PIK3CA* mutation in 17 (13%); *NRAS* mutation in one (1%); *KIF5b-RET* fusion in one (1%); *EGFR* copy number gain in six (5%); *PIK3CA* copy number gain in 19 (15%); and *FGFR1* copy number gain in six (5%) (Additional file [3](#MOESM3){ref-type="media"}: Table S2 and Additional file [4](#MOESM4){ref-type="media"}: Table S3). Of eight patients with *EGFR* mutation, four had the L858R point mutation in exon 21, and three had deletions in exon 19. In addition, the frequencies of genetic alterations in surgically-resected, snap-frozen samples and FFPE samples from patients with squamous cell lung cancer were analyzed (Figure [2](#Fig2){ref-type="fig"}), and the following alterations were detected: *EGFR* mutation in 8% and 5%, *KRAS* mutation in 3% and 5%, *PIK3CA* mutation in 17% and 9%, *EGFR* copy number gain in 8% and 2%, *PIK3CA* copy number gain in 19% and 11%, and *FGFR1* copy number gain in 8% and 2%, respectively.Figure 1**Relative proportions of genetic alterations in squamous cell lung cancer and adenosquamous carcinoma (overall, n = 129). A**: Pie chart shows relative proportions of genetic alterations. **B**: Bar chart shows relative proportions of genetic alterations. MUT: mutant, CNG: copy number gain.Figure 2**Relative proportions of genetic alterations in surgically resected snap-frozen samples (A and B, n = 64) and paraffin-embedded samples (C and D, n = 65) from patients with squamous cell lung cancer and adenosquamous carcinoma. A**: Bar chart shows relative proportions of genetic alterations in surgically resected snap-frozen samples. **B**: Pie chart shows relative proportions of genetic alterations in surgically resected snap-frozen samples. **C**: Bar chart shows relative proportions of genetic alterations in paraffin-embedded samples. **D**: Pie chart shows relative proportions of genetic alterations in paraffin-embedded samples. MUT: mutant, CNG: copy number gain.

Clinicopathological factors related to genetic alterations {#Sec9}
----------------------------------------------------------

The results of univariate analysis of clinicopathological factors for genetic alterations are shown in Table [3](#Tab3){ref-type="table"}. Genetic alterations were significantly more frequent in surgically-resected, snap-frozen samples than in FFPE samples (50% vs. 29%, p = 0.015). In addition, patients ≤70 years old and "never-smokers" showed higher frequencies of genetic alterations. Also, 75% of patients ≤60 years old (n = 12) had genetic alterations including *EGFR* mutation in 2, *KRAS* mutation in 2, *PIK3CA* mutation in 2, *KIF5b-RET* fusion in 1, *EGFR* copy number gain in 2, and *PIK3CA* copy number gain in 2.Table 3**Frequency of genomic alterations in clinicopathological factors (overall, n =129)**Genomic alterationsp value(+)(-)Age0.027    ≤70 years3335    \>70 years1848GenderN.S.    Male4467    Female711Smoker0.035    Never310    Light (pack-year \<30)39    Heavy (pack-year ≥30)4569HistologyN.S.    Squamous4974    Adenosquamous24DifferentiationN.S.    Well58    Moderately2742    Poorly1520    Unknown24StageN.S.    I1320    II1226    III1618    IV1014Samples0.015    Snap-frozen3232    FFPE1946*FFPE* formalin-fixed paraffin-embedded.

Discussion {#Sec10}
==========

This study represents one of the largest, prospective, tumor-genotyping studies carried out in Asian patients with squamous cell carcinoma of the lung. Genetic alterations were detected in 40% of patients in this study. There have been few reports on the gene alterations associated with squamous cell lung cancer. However, the Cancer Genome Atlas Research Network performed a comprehensive genomic analysis of 178 squamous cell lung cancers and reported the following genetic alterations: *PIK3CA* mutations in 16%, *PTEN* mutation/deletion in 15%, *FGFR1* amplification in 15%, *EGFR* amplification in 9%, *PDGFRA* amplification in 9%, *DDR2* mutation in 4%, and unknown genetic alterations in 21% \[[@CR8]\]. In addition, multiplex testing for driver mutations in 72 squamous cell carcinomas of the lung detected: *PIK3CA* mutations in 8%, *PTEN* mutation/deletion in 28%, *FGFR1* amplification in 26%, and unknown genetic alterations in 39% \[[@CR9]\]. Korean study showed a similar spectrum of gene alterations between East Asian and North American \[[@CR10]\]. Genetic alterations in patients enrolled in the current prospective study may reflect the frequencies of genetic alterations in the clinical setting, and suggest that genetic profiling in Japanese patients may be similar to that in North American.

Genetic alterations were seen more frequently in surgically-resected, snap-frozen samples, in patients ≤70 years old, and in "never-smokers". FFPE specimens are subject to increasing DNA degradation as they get older \[[@CR17]\], which may account for the difference in frequencies of genetic alterations between snap-frozen and FFPE samples. Squamous cell lung cancer is strongly associated with cigarette smoking \[[@CR18]\] and 98% of patients with squamous cell carcinoma in this study were light or heavy smokers. Although all three "never-smokers" showed genetic alterations (*EGFR* mutation, *EGFR* or *PIK3CA* copy number gain), the sample size was too small to evaluate these results. The association between age and genetic alterations is unclear. Multiple genetic alterations were reported to be more common in younger patients with papillary thyroid cancer \[[@CR19]\], while younger patients with colorectal cancer showed a high frequency of KRAS mutations \[[@CR20]\]. In contrast however, a positive association between *EGFR* mutation and age was reported among never-smoker lung cancer patients \[[@CR21]\].

In this study, *PIK3CA* mutation was relatively frequent in squamous cell lung cancer, as reported in other studies, while *FGFR1* copy number gain seemed less frequent \[[@CR8], [@CR9]\]. The phosphoinositide 3-kinase (PI3K) pathway is a key oncogenic signaling pathway that functions in cell survival and proliferation \[[@CR22]\]. The *PIK3CA* gene encodes the PI3K catalytic subunit α-isoform and is frequently mutated in some of the most common human tumors. Our earlier study, as well as other studies, found that *PIK3CA* mutations were more common in squamous cell lung cancer than in lung adenocarcinoma \[[@CR23]--[@CR25]\]. The fibroblast growth factor receptor (FGFR) is a transmembrane receptor tyrosine kinase that participates in the regulation of embryonal development, cell proliferation, differentiation, and angiogenesis \[[@CR26], [@CR27]\]. The frequency of *FGFR1* amplification in surgical specimens has been reported to be 13--41%, and does not seem to differ according to ethnicity \[[@CR28]--[@CR30]\]. However, the frequency of *FGFR1* copy number gain in this study was only 4% of all samples and 8% of fresh-frozen samples. This apparent discrepancy in the frequencies of *FGFR1* copy number gain may be a result of the different methodologies used in the studies, and/or the influence of biopsy samples from patients with metastatic squamous cell lung cancer. *PIK3CA* mutation and *FGFR1* amplification both represent potential targets for personalized squamous cell lung cancer therapy, and it may therefore be important to analyze both these gene alterations in clinical practice.

A major limitation of this study was that genetic alterations were analyzed using a genotyping panel, rather than by a comprehensive analysis. However, the objective of this study was not only to assess the frequencies of driver gene mutations, but also to assign patients to appropriate therapies and/or enrollment in clinical trials. Our genotyping panel included most gene mutations that are targeted by new drugs in ongoing clinical trials. This study was also limited by intratumor heterogeneity, which may have resulted in underestimation of tumor genetic alterations \[[@CR31]\]. It is difficult to obtain multiple lesions by tumor biopsy in the clinical setting, but we intend to address this challenge in the future to aid further progress in biomarker development.

Conclusion {#Sec11}
==========

Genetic alterations were detected in 40% of Japanese patients with squamous cell lung cancer. These results suggest that incorporation of genetic profiling into lung cancer clinical practice may facilitate the administration of personalized cancer treatments in patients with squamous cell lung cancer, though further studies are needed to verify these results.
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